Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metastatic Pancreatic Cancer

Exclusion Criteria

• •1. Patient who have had any prior chemotherapy within 5 years of enrollment.
• •2. Patient who have had radiotherapy for pancreatic cancer.
• •3. Age ≥ 76 years
• •4. Patient who is receiving or have received any other investigational agents within 28 days prior to Day 1 of treatment in this study.
• •5. Patient who has undergone major surgery, other than diagnostic surgery within 28 days prior to Day 1 of treatment in this study.
• •6. Patient who has known brain metastases.
• •7. Patient with history of hypersensitivity or allergic reactions attributed to compounds of similar chemical or biologic composition to gemcitabine, taxotere, xeloda, cisplatin, or irinotecan.
• •8. Patient with uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
• •9. Patient who has serious medical risk factors involving any of the major organ systems.
• •10. Patient who has known history of infection with HIV, hepatitis B, or hepatitis C.
• •11. Pregnant or breast feeding.
• •12. Patient is unwilling or unable to comply with study procedures
• •13. Patient with clinically significant wound